NCT01392105 (SEED-MSC) is a Phase 2/Phase 3 clinical trial of Mesenchymal stem cell in Acute Myocardial Infarction, sponsored by Yonsei University.

Who is sponsoring NCT01392105?

NCT01392105 is sponsored by Yonsei University.

What drugs are being tested in NCT01392105?

Interventions in NCT01392105: Mesenchymal stem cell, Control group.

What condition does NCT01392105 study?

NCT01392105 studies Acute Myocardial Infarction.

Is NCT01392105 still recruiting?

NCT01392105 is currently completed. Last updated 11 July 2011.

Last reviewed 2011-07-11 · How we verify

NCT01392105: SEED-MSC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction

Completed Phase 2/Phase 3 Last updated 11 July 2011

What this trial tests

Phase 2/Phase 3 trial testing Mesenchymal stem cell in Acute Myocardial Infarction in 80 participants. Completed in 1 May 2010.

Timeline

1 March 2007

Primary endpoint
1 May 2010

1 May 2010

Quick facts

Lead sponsor	Yonsei University
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 March 2007
Primary completion	1 May 2010
Estimated completion	1 May 2010
Sites	3 locations across South Korea

Drugs / interventions tested

Mesenchymal stem cell
Control group — full drug profile →

Conditions studied

Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →

Sponsor

Yonsei University

Who can join

Adults 18 to 70, any sex, with Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Absolute changes in global LVEF by SPECT
Time frame: baseline and 6 months
Absolute changes in global left ventricular ejection fraction (LVEF) as measured by SPECT 6 months after cell infusion

Sponsor's own description

Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause of death worldwide. Current management strategies cannot solve the problem of cardiomyocyte loss and consequent progression of heart failure. In this respect, stem-cell therapy has shown potential benefits for repairing the damaged myocardium. Mesenchymal stem cells (MSCs) have been considered to be attractive therapeutic candidates because of their high capacity for replication: paracrine effect: ability to preserve potency: and because they do not cause adverse reactions to allogeneic versus autologous transplants. Intracoronary injection of stem cells seems to be safe, but only one clinical trial using MSCs via the intracoronary route in the setting of acute myocardial infarction (AMI) has been carried out. The investigators therefore assessed the safety and efficacy of intracoronary autologous bone marrow (BM)-derived human MSCs in patients with AMI.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical applications of mesenchymal stem cells.
Wang S, Qu X, Zhao RC. · · 2012 · cited 307× · PMID 22546280 · DOI 10.1186/1756-8722-5-19
The therapeutic potential of mesenchymal stem cells for cardiovascular diseases.
Guo Y, Yu Y, Hu S, Chen Y, et al · · 2020 · cited 207× · PMID 32393744 · DOI 10.1038/s41419-020-2542-9
The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential.
Watt SM, Gullo F, van der Garde M, Markeson D, et al · · 2013 · cited 193× · PMID 24152971 · DOI 10.1093/bmb/ldt031
A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies.
Saeedi P, Halabian R, Imani Fooladi AA. · · 2019 · cited 170× · PMID 31620481 · DOI 10.21037/sci.2019.08.11
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).
Singh A, Singh A, Sen D. · · 2016 · cited 137× · PMID 27259550 · DOI 10.1186/s13287-016-0341-0
A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction.
Lee JW, Lee SH, Youn YJ, Ahn MS, et al · · 2014 · cited 118× · PMID 24431901 · DOI 10.3346/jkms.2014.29.1.23
Stem cell treatment for acute myocardial infarction.
Fisher SA, Zhang H, Doree C, Mathur A, et al · · 2015 · cited 93× · PMID 26419913 · DOI 10.1002/14651858.cd006536.pub4
Approaches to therapeutic angiogenesis for ischemic heart disease.
Johnson T, Zhao L, Manuel G, Taylor H, et al · · 2019 · cited 86× · PMID 30554258 · DOI 10.1007/s00109-018-1729-3

Verify or expand the search:

Other trials of Mesenchymal stem cell

Trials testing the same drug.

NCT05433298 — Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19. · Phase 1, PHASE2 · withdrawn
NCT04888949 — A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19) · Phase 2 · completed
NCT03362424 — Mesenchymal Stem Cells in Rotator Cuff Repair · Phase 2 · suspended
NCT04522986 — An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection · Phase 1 · completed
NCT03164083 — The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarth · Phase 2 · withdrawn

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01392105 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 11 July 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01392105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing